UNSPSC 51143400: Combination antimigraine agents

This classification denotes combination drugs that treat primary headache disorders which feature recurrent unilateral pulsatile headaches of types classic (with visible aura neurological symptoms) and type common migraine (without visible aura), headaches commonly called migraines, hence the term ANTIMIGRAINE AGENTS. Typical combination antimigraine agent constituents are acetaminophen, belladonna, caffeine, ergotamine, and naproxen.

UNSPSC 51143400 Combination antimigraine agents is a Class code that in state and local practice encompasses the procurement of pharmaceutical products and drug management systems supporting community health initiatives, emergency response, and pharmacy benefit programs. Recent solicitations under this code show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription fulfillment capabilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Scope varies from tactical procurement of specific emergency-response pharmaceuticals to strategic contracting for ongoing pharmaceutical supply chains serving multiple jurisdictions and eligible populations.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling future formal procurement. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers; the contract term begins July 1, 2026. Vendors must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and maintain specified insurance coverages. Pricing models vary across opportunities, from fixed-fee bids to competitive net-price and WAC-minus structures, with MMCAP applying a 3 percent administrative fee on all contract purchases.